Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 9/20 | 0.82 |
| ▸ | CDK2 | P24941 | 9/20 | 0.82 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.82 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.82 |
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | NPC1 | O15118 | 2/20 | 0.82 |
| ▸ | GSK3A | P49840 | 1/20 | 0.82 |
| ▸ | GSK3B | P49841 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7757586 | 0.95 | CCNA2 (0.82) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL4398263 | 0.93 | CDK5 (0.72) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL20142073 | 0.91 | CCNA2 (0.68) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL1248419 | 0.91 | CCNA2 (1.00) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL5724765 | 0.90 | CCNA2 (0.87) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL25609626 | 0.88 | CCNA2 (0.85) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL1250519 | 0.88 | CCNA2 (0.85) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL13633763 | 0.88 | CDK5 (0.65) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL20142846 | 0.88 | CCNA2 (0.78) | CCNA2CDK2CDK5CDK5R1MAPT | |
| SCHEMBL20142403 | 0.88 | CCNA2 (0.78) | CCNA2CDK2CDK5CDK5R1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089902-A1 | DIAMINOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2018-05-17 | — | — | WO | claimed |
| WO-2018089902-A1 | DIAMINOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2018-05-17 | — | — | WO | disclosed |
| US-8829014-B2 | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2007393-B1 | THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS | UNIV LOUISIANA STATE (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120283268-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | GIORDANO ANTHONY (US) | 2012-11-08 | — | — | US | disclosed |
| US-8217037-B2 | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2012-07-10 | — | — | US | disclosed |
| US-20090306073-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | B.V. PATEL PHARMACEUTICAL EDUCATION & RESEARCH DEVELOPMENT (PERD) CENTRE (IN) | 2009-12-10 | — | — | US | disclosed |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056567-A1 | 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS | NOVO NORDISK A/S (DK) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306073-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | TPMT, TST, SSB | CCNA2 2213/4885CDK2 409/4885CDK5 732/4885 |
| US-20120283268-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | TPMT, TST, SSB | CCNA2 2213/4885CDK2 409/4885CDK5 732/4885 |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | GSK3A, GSK3B, GSKIP | CCNA2 3738/4885CDK2 566/4885CDK5 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.